 | Up a level |
Michel, Christian; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Neubauer, Andreas; Lauseker, Michael; Krause, Stefan W; Kolb, Hans-Jochem; Hossfeld, Dieter Kurt; Nerl, Christoph; Baerlocher, Gabriela M.; Heim, Dominik; Brümmendorf, Tim H; Fabarius, Alice; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Goebeler, Maria-Elisabeth; Hänel, Mathias; Ho, Anthony; ... (2019). Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica - the hematology journal, 104(5), pp. 955-962. Ferrata-Storti Foundation 10.3324/haematol.2018.206797
Eich, Hans Theodor; Diehl, Volker; Görgen, Helen; Pabst, Thomas; Markova, Jana; Debus, Jürgen; Ho, Anthony; Dörken, Bernd; Rank, Andreas; Grosu, Anca-Ligia; Wiegel, Thomas; Karstens, Johann Hinrich; Greil, Richard; Willich, Normann; Schmidberger, Heinz; Döhner, Hartmut; Borchmann, Peter; Müller-Hermelink, Hans-Konrad; Müller, Rolf-Peter and Engert, Andreas (2010). Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of clinical oncology, 28(27), pp. 4199-206. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.29.8018
